Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells

Correction to: Cancer Immunol Immunother 10.1007/s00262-017-2073-0

The authors would like to make the following corrections to the published article:

Prior therapy for Patient 3 was high-dose IL-2, vemurafenib, ipilimumab, and dabrafenib (Table 1).

TIL 1383I TCR complexes were tethered to the CM5 sensor surface and HLA-A2-tyrosinase complexes were injected over the surface (Methods and Fig. 5).

The solution (3D) affinity of the TIL 1383I TCR was 13 μM (Fig. 5a and text).